Advertisement

Carcinoma of the Kidney: Biological Markers

  • M. R. G. Robinson
  • D. Daponte
  • C. Chandrasekaran
Part of the NATO Advanced Science Institutes Series book series (NSSA, volume 53)

Abstract

During the development and progression of malignant disease, certain biological products (markers) are produced by, or in response to, the tumour. They may be specific for a particular tumour, or non-specific, and have a potential value in diagnosis, screening, staging, prognosis, the choice of treatment, monitoring disease progression, and evaluation of the response to treatment. Improved biochemical and immunological techniques have made possible their identification, characterisation and availability for clinical use (1).

Keywords

Renal Cell Carcinoma Tumour Marker Renal Tumour Renal Cancer Renal Carcinoma 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. 1.
    B. Wahren, Tumour Markers in Urology: Aids in Cancer Diagnosis and Management, Urol. Res. 7:56 (1979).CrossRefGoogle Scholar
  2. 2.
    N. Javadpour, Tumour Markers in Urologic Cancer, Urology, 16:127, (1980).PubMedCrossRefGoogle Scholar
  3. 3.
    G. Surfin, E.A. Mirona, R.H. Moore, T.M. Chu and G.P. Murphy, Hormones and Renal Cancer, J. Urol. 117:433 (1977).Google Scholar
  4. 4.
    L.F. Altaffer and O.W. Chenault, Paraneoplastic Endocrinopathies Associated with Renal Tumours, J. Urol. 122:573 (1979).PubMedGoogle Scholar
  5. 5.
    J.B. DeKernion, K.P. Ramming and R.K. Gupta, The Detection and Clinical Significance of Antibodies to Tumour-Associated Antigens in Patients with Renal Cell Carcinoma, J. Urol. 122:300 (1979).PubMedGoogle Scholar
  6. 6.
    T.M. Chu, S.K. Shukla, A.O. Mittleman and G.P. Murphy, Plasma Carcinoembryonic Antigen in Renal Cell Carcinoma Patients, J. Urol. 111:742 (1974).PubMedGoogle Scholar
  7. 7.
    E.M. Sanford, J.R. Drago, T.J. Rohner, G.F. Kessler, L. Sheehan and A. Lipton, Preliminary Evaluation of Urinary Polyamines in the Diagnosis of Genitourinary Tract Malignancy, J. Urol. 113:218 (1975).PubMedGoogle Scholar
  8. 8.
    K.B. Cummings and R.P. Robertson, Prostaglandin: Increased Production by Renal Cell Carcinoma, J. Urol. 118:720 (1977).PubMedGoogle Scholar
  9. 9.
    R.M. Zusman, J.J. Snider, A. Cline, B.V. Caldwell and L. Speroff, Antihypertensive Function of a Renal Cell Carcinoma. Evidence for a Prostaglandin A Secreting Tumour, New Eng. J. Med. 29:843 (1974).CrossRefGoogle Scholar
  10. 10.
    J. Lee, H. Konnegiesser, J. O’Toole and E. Westura, Hypertension and Renomedullary Prostaglandins: A Human Study of Antihypertensive Effects of PGA, Ann. N.Y. Acad. Sci. 180:218 (1971).PubMedCrossRefGoogle Scholar
  11. 11.
    E.H. Cooper and A. Milford Ward, Acute Phase Reactant Proteins as Aids to Monitoring Disease, Invest. Cell. Path. 2:293 (1979).Google Scholar
  12. 12.
    M. Vickers, Serum Haptoglobins: A Pre-Operative Detector of Metastatic Renal Carcinoma, J. Urol. 112:310 (1974).PubMedGoogle Scholar
  13. 13.
    B. Richards, M.R.G. Robinson, N.B. Pidcock and E.H. Cooper, Serum Protein Profiles in Carcinoma of the Kidney, Eur. Urol. (in press).Google Scholar

Copyright information

© Springer Science+Business Media New York 1983

Authors and Affiliations

  • M. R. G. Robinson
    • 1
  • D. Daponte
    • 1
  • C. Chandrasekaran
    • 1
  1. 1.The General InfirmaryPontefractUK

Personalised recommendations